The expansion of the public economy: A comparative analysis

DR Cameron - American political science review, 1978 - cambridge.org
In spite of the traditional legitimacy accorded the market mechanism of the private sector in
advanced capitalist nations, governments in those nations have become more influential as …

Strategic Recovery? The Conservatives Under David Cameron

J Green - Parliamentary Affairs, 2010 - academic.oup.com
David Cameron increased the Conservative party's vote … Winning 307 seats in parliament
in 2010, David Cameron failed to … It traces the journey of David Cameron's Conservatives in …

Consigning its past to history? David Cameron and the Conservative Party

S Evans - Parliamentary Affairs, 2008 - academic.oup.com
David Cameron's elevation to the leadership of the Conservative Party on 6 December 2005
must be seen. The main reason why CameronCameron over the supposed favourite, David

[HTML][HTML] Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer

…, G Meinhardt, N Harbeck, DA Cameron - … England Journal of …, 2022 - Mass Medical Soc
Background Among breast cancers without human epidermal growth factor receptor 2 (HER2)
amplification, overexpression, or both, a large proportion express low levels of HER2 that …

[HTML][HTML] Conservation planning for ecosystem services

KMA Chan, MR Shaw, DR Cameron… - PLoS …, 2006 - journals.plos.org
Despite increasing attention to the human dimension of conservation projects, a rigorous,
systematic methodology for planning for ecosystem services has not been developed. This is …

[HTML][HTML] Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

…, R Bell, C Jackisch, D Cameron… - … England Journal of …, 2005 - Mass Medical Soc
Background Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical
activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and …

[HTML][HTML] Lapatinib plus capecitabine for HER2-positive advanced breast cancer

…, C Oliva, SD Rubin, S Stein, D Cameron - New England journal …, 2006 - Mass Medical Soc
Background Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor
receptor type 2 (HER2, also referred to as HER2/neu) and epidermal growth factor receptor (EGFR), …

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

…, JP Costantino, N Wolmark, H Bonnefoi, D Cameron… - The Lancet, 2014 - thelancet.com
Background Pathological complete response has been proposed as a surrogate endpoint
for prediction of long-term clinical benefit, such as disease-free survival, event-free survival (…

[HTML][HTML] Ribociclib as first-line therapy for HR-positive, advanced breast cancer

…, P Conte, CL Arteaga, DA Cameron… - New England journal …, 2016 - Mass Medical Soc
Background The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially
overcome or delay resistance to endocrine therapy in advanced breast cancer that is positive …

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

…, G Mariani, J Baselga, M Kaufmann, D Cameron… - The lancet, 2007 - thelancet.com
Background Trastuzumab—a humanised monoclonal antibody against HER2—has been
shown to improve disease-free survival after chemotherapy in women with HER2-positive …